Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.13
<$0.01(1.03%)
At close: 4:00 PM EDT
$0.13
<$0.01(1.03%)
Day’s Range― - ―
52-Week Range$0.10 - $1.40
Previous Close$0.13
Volume406.85K
Average Volume (3M)169.78K
Market Cap
$2.07M
Enterprise Value-$5.98
Total Cash (Recent Filing)$10.05M
Total Debt (Recent Filing)$343.33K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding16,192,438
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Diversification Into Cosmetics And Biotech ToolsShifting resources to nearer-term cosmetics (ATR-COSF) and biotech tools broadens commercialization pathways beyond high-risk therapeutics. This creates multiple, staggered value drivers with shorter time-to-market, improving chance of sustainable revenue and reducing binary clinical dependence over the next 2–4 years.
Proprietary Strain Library And AI/ML Discovery PlatformA large, curated microbial library plus AI/ML discovery is a structural competitive advantage: it enables repeated product generation, platform scalability and potential licensing. That durable R&D engine supports multiple programs and partnerships, lowering marginal discovery costs and enabling pipeline breadth.
Improved Capitalization And Manageable LeverageStronger headline capitalization and modest debt reduce near-term solvency risk and provide flexibility to execute strategic pivots. While losses persist, a healthier balance sheet buys time for commercialization or partnership outcomes and lowers immediate refinancing pressure versus prior weak-capital periods.
Bears Say
Severe Negative Cash Generation And Worsening Cash FlowPersistently negative operating and free cash flow that worsened in the TTM signals structural cash burn. This depletes runway absent recurring revenue or sizable financing, increasing dilution risk and forcing trade-offs that can delay R&D, commercialization or partnering over the next several quarters.
Revenue Volatility And Lack Of Recurring Commercial ScaleA one-time revenue spike followed by zero reported revenue reflects no stable commercial base. Without recurring sales, margins and operating leverage remain unattainable, making sustained profitability unlikely and increasing dependency on non-operating financing or one-off transactions to fund operations.
Governance And Execution FragilityAn adjourned annual meeting for lack of quorum signals shareholder disengagement and governance weakness. Combined with paused ATR-12 enrollment and financing-driven decisions, this raises execution risk: board/stakeholder alignment and timely strategy implementation may be impaired during critical funding and clinical decision points.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $1.40 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $2.07M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Aug 17, 2026 which is in 17 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on May 13, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.24.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Undervalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.12.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 16,192,438 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
AZTR Stock 12 Month Forecast
Average Price Target
$1.00
▲(669.23% Upside)
Technical Analysis
Ownership Overview
27.62% Insiders
0.47% Mutual Funds
0.14% Other Institutional Investors
71.76% Public Companies and
Individual Investors